May 2014

ADC SUMMIT

19th May to 20th May 2014, Holiday Inn Regents Park Hotel, London, United Kingdom

Antibody Drug Conjugates (ADCs) offer the promise and potential of delivering powerful tumour-killing activity with the advantage of reduced side effects for cancer patients. While one of the biggest challenges in manufacturing these powerful ADCs is controlling all the components that go into the final conjugation step, researchers do believe that further improvements and research in ADC design can and are resulting in a new generation of agents

Following on from the success of past events,SMI are proud to present 3rd annual Antibody Drug Conjugates Summit, 19th-20th May 2014, London. Focusing on innovative manufacturing techniques, preclinical and clinical data and next generation ADCs, this important and timely meeting will bring together key industry experts from academia and large and small pharma and biotech companies.

Join us and hear case studies, presentations and round tables demonstrating how to maximise the therapeutic index of your ADC and how this form of empowered antibody is transforming next-generation antibody therapeutics. This must attend event will be delivered by true industry experts who will inform you of latest developments.

Key Topics include:

• Exploring nano-delivery systems
• Advancing preclinical development to accelerate ADCs into the clinic
• Refining next generation ADCs
• Learn how to overcome manufacturing challenges

Pain Therapeutics

19th May to 20th May 2014, Holiday Inn Regents Park Hotel, London, United Kingdom

SMi are proud to present their 14th Annual Pain Therapeutics Conference taking place in Central London on Monday 19th and Tuesday 20th May 2014.

This event will focus on the advances and challenges of pre-clinical and clinical aspects of pain drug development.

The agenda will give delegates an in-depth analysis on the strategies from bench to bedside to enhance drug development.

New mechanisms will also play an important role when evaluating novel targets with alternative approaches to animal ‘pain’ models and personalised medicines as an exploratory area.

The translation gap between animal data and humans is significant, enabling delegates to review proof of concept for pain modelling in humans.

New sessions for 2014 will include:

• Advances in recent neuropathic pain developments will be studied, in addition to assessing new therapeutic strategies for pain reduction

ADC SUMMIT

19th May to 20th May 2014, Holiday Inn Regents Park Hotel, London, United Kingdom

Antibody Drug Conjugates (ADCs) offer the promise and potential of delivering powerful tumour-killing activity with the advantage of reduced side effects for cancer patients. While one of the biggest challenges in manufacturing these powerful ADCs is controlling all the components that go into the final conjugation step, researchers do believe that further improvements and research in ADC design can and are resulting in a new generation of agents

Following on from the success of past events,SMI are proud to present 3rd annual Antibody Drug Conjugates Summit, 19th-20th May 2014, London. Focusing on innovative manufacturing techniques, preclinical and clinical data and next generation ADCs, this important and timely meeting will bring together key industry experts from academia and large and small pharma and biotech companies.

Join us and hear case studies, presentations and round tables demonstrating how to maximise the therapeutic index of your ADC and how this form of empowered antibody is transforming next-generation antibody therapeutics. This must attend event will be delivered by true industry experts who will inform you of latest developments.

Key Topics include:

• Exploring nano-delivery systems
• Advancing preclinical development to accelerate ADCs into the clinic
• Refining next generation ADCs
• Learn how to overcome manufacturing challenges

Pain Therapeutics

19th May to 20th May 2014, Holiday Inn Regents Park Hotel, London, United Kingdom

SMi are proud to present their 14th Annual Pain Therapeutics Conference taking place in Central London on Monday 19th and Tuesday 20th May 2014.

This event will focus on the advances and challenges of pre-clinical and clinical aspects of pain drug development.

The agenda will give delegates an in-depth analysis on the strategies from bench to bedside to enhance drug development.

New mechanisms will also play an important role when evaluating novel targets with alternative approaches to animal ‘pain’ models and personalised medicines as an exploratory area.

The translation gap between animal data and humans is significant, enabling delegates to review proof of concept for pain modelling in humans.

New sessions for 2014 will include:

• Advances in recent neuropathic pain developments will be studied, in addition to assessing new therapeutic strategies for pain reduction